EUVIMEDEUVIMED entdecken
Open Access

Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma

Pooja A Shah, Tuhina Mazumdar, Soma Ghosh, Lacin Yapindi, Reid T Powell, Yong S Park, Li Shen, Anne M Fernandez, Clifford C Stephan, Jing Wang, Andrew G Sikora, Jawad Kazi und 2 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Pooja A Shah und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Receptor, Notch1, Apoptosis, Protein Serine-Threonine Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, CPRIT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PI3K inhibition causes apoptosis selectively in NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC), but modest single-agent responses and acquired resistance (AR) limit the clinical efficacy of targeted agents. To address these limitations, we investigated novel combination therapies. We tested the efficacy of 5768 compounds as single agents and 139 in combination with PI3K inhibitors in sensitive and AR NOTCH1-mutant HNSCC cell lines. We generated synergy/efficacy classifications for the combinations using multiple metrics of statistical drug synergy and growth rate indices. The PLK1/PI3K combination's efficacy was validated using orthogonal in vitro methods and in two HNSCC xenograft models. Compound efficacy was enriched in 30 of 306 drug classes. Drugs from nine classes enhanced the cell killing of PI3K inhibition. We pursued experiments with PLK1 inhibitors based on clinical relevance and efficacy in parental and AR models. The combination of PLK1 and PI3K inhibition caused apoptosis, DNA damage, and immunogenic cell death in vitro and extended survival in vivo. PLK1 activity decreased following PI3K inhibition only in sensitive NOTCH1-mutant HNSCC cell lines and not in AR or resistant wild-type cells. The combination of PI3K and PLK1 inhibition causes robust killing of HNSCC and overcomes PI3K inhibitor resistance. Specific and well-tolerated PI3K and PLK1 inhibitors that do not have overlapping toxicity are in clinical development. We hypothesize that this combination may have a wide therapeutic window with significant efficacy but modest toxicity because it should spare normal cells that have wild-type NOTCH1 and are not sensitive to PI3K inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Notch1ApoptosisProtein Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsCell Cycle ProteinsHead and Neck NeoplasmsMutationProto-Oncogene ProteinsCarcinoma, Squamous CellProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansPolo-Like Kinase 1AnimalsSquamous Cell Carcinoma of Head and NeckCell Line, TumorXenograft Model Antitumor AssaysDrug SynergismMiceDrug Resistance, NeoplasmMice, NudeSignal Transduction

Stichwörter der Autor:innen

Head and neck squamous cell carcinomaNOTCH1PI3KPolo-like kinase 1

Substanzen

Receptor, Notch1Polo-Like Kinase 1NOTCH1 protein, humanProtein Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsCell Cycle ProteinsProto-Oncogene ProteinsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Center for Translational Cancer Research, Institute of Biosciences and Technology Texas A&M University College of Medicine, Houston, TX, USA.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Otolaryngology, Baylor College of Medicine, Houston, TX, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • CPRIT
  • Takeda Pharmaceuticals U.S.A.
  • National Institutes of Health

Zitieren

APA

Shah, P. A., Mazumdar, T., Ghosh, S., Yapindi, L., Powell, R. T., Park, Y. S., Shen, L., Fernandez, A. M., Stephan, C. C., Wang, J., Sikora, A. G., Kazi, J., Frederick, M. J., & Johnson, F. M. (2025). Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217814

Vancouver

Shah PA, Mazumdar T, Ghosh S, Yapindi L, Powell RT, Park YS, et al. Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217814

BibTeX
@article{Shah2025,
  author = {Shah, Pooja A and Mazumdar, Tuhina and Ghosh, Soma and Yapindi, Lacin and Powell, Reid T and Park, Yong S and Shen, Li and Fernandez, Anne M and Stephan, Clifford C and Wang, Jing and Sikora, Andrew G and Kazi, Jawad and Frederick, Mitchell J and Johnson, Faye M},
  title = {Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217814}
}
Kostenlos starten →